Compounded Semaglutide & Tirzepatide Are Going Away: Your 2026 Options

If you have been getting compounded semaglutide or tirzepatide through telehealth for $100–250 a month, the ground has shifted. The FDA-declared shortages that made mass compounding legal ended in 2025, and in May 2026 the FDA proposed permanently barring outsourcing facilities from compounding these drugs at all. This is not a drill, but it is also widely misreported — so here is the honest version of what has actually happened, what is still only proposed, and the four real paths forward (pay for brand, switch to the new oral pill, taper off, or — the one to avoid — the gray market). This is a decision guide; it links to our detailed cost, switching, and compounded-vs-brand deep-dives for the numbers.

The bottom line

• Mass compounding already ended in 2025 — not 2026. Once the FDA declared the shortages over (tirzepatide Dec 2024, semaglutide Feb 2025), the legal basis for compounding "copies" went away. Compounding wound down on set deadlines through spring 2025.
• The big May 2026 news is a PROPOSAL, not a ban. On May 1, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the comment period closed June 29, 2026). It is pending — not finalized and not in effect. Anyone telling you compounding was "banned in May 2026" is overstating it.
• A narrow personalized-compounding door remains — for now. A state-licensed (503A) pharmacy can still compound a genuinely non-copy formulation only when your prescriber documents a clinically significant change for you specifically; the FDA has also said it will not pursue a 503A pharmacy filling four or fewer of a given compounded product per month. Blanket "weight-loss + B12" justifications do not qualify. A few states add their own rules on top — see our state-by-state legality tracker.
• You have four real options: switch to brand at the new lower direct-pay prices, switch to the oral pill, taper off (with eyes open about weight regain), or — do not — buy "research" peptides from the gray market.

What actually happened: the timeline

Compounding of these drugs was only legal because they were on the FDA drug-shortage list. Once the shortages resolved, that window closed on a schedule:

• Tirzepatide (Mounjaro/Zepbound): shortage declared resolved Dec 19, 2024. State-licensed (503A) compounding ended Feb 18, 2025; outsourcing-facility (503B) compounding ended Mar 19, 2025.
• Semaglutide (Ozempic/Wegovy): shortage resolved Feb 21, 2025. 503A compounding ended Apr 22, 2025; 503B ended May 22, 2025.
• A lawsuit did not stop it: the Outsourcing Facilities Association sued, but a court denied the preliminary injunction on April 24, 2025 — the deadlines stood.
• May 1, 2026 — the permanent proposal: the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B "bulks list" (finding no clinical need to compound them from bulk drug substance). This was published in the Federal Register; the comment period closed June 29, 2026. It is still pending FDA review — not final.
• Enforcement is real: the FDA has issued repeated waves of warning letters to telehealth companies (roughly 80 in Sept 2025 and about 25 more in June 2026) for marketing compounded GLP-1s as if they were FDA-approved or equivalent to the brand. It has also tied the crackdown to more than 1,700 adverse-event reports involving compounded GLP-1s.

Your options, in plain terms

1. Switch to the brand — the price gap has narrowed a lot. The manufacturers cut self-pay prices in 2025–2026: Zepbound (tirzepatide) self-pay vials run roughly $299–$449/month through LillyDirect, and Wegovy (semaglutide) is around $499/month (some doses lower) through NovoCare — versus the ~$1,300 retail list price. That is still more than compounded was, but the difference is a fraction of what it used to be. See our cheapest-GLP-1 buyer's guide and compounded-vs-branded decision guide for the current math, and our semaglutide and tirzepatide provider rankings. (Prices change often — confirm the current figure before you commit.)

2. Switch to the oral pill. There is now a brand-adjacent, lower-cost oral route: orforglipron (Foundayo) was FDA-approved in April 2026, with self-pay pricing starting around $149/month and no food-or-water timing restrictions, and an oral semaglutide pill for weight loss was approved in late 2025. See our oral-vs-injectable comparison to weigh magnitude against convenience and cost.

3. Taper or stop — but know the rebound math. Stopping is a legitimate choice, but the trials are blunt about what usually happens: in the semaglutide withdrawal trial (STEP-4^[1]), people who switched to placebo regained weight while those who continued kept losing; in the tirzepatide withdrawal trial (SURMOUNT-4^[2]), most participants regained a large share of their lost weight after stopping, and blood-pressure, lipid, and glucose improvements drifted back toward baseline. If you taper, do it with your prescriber and a maintenance plan, not cold turkey.

Switching drugs? Get the dose right

If the sunset pushes you from one drug to the other, the single most important safety rule is: always restart tirzepatide at 2.5 mg (and semaglutide at 0.25 mg), regardless of the dose you were on — the two drugs hit different receptors and there is no FDA-validated dose equivalence between them. Our semaglutide-to-tirzepatide switching guide covers the washout, the practice-based (not official) dose mapping, and what to expect; if you are moving between the pill and an injection, see the Foundayo–Zepbound switching guide.